Search Results

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Quidel Corporation announced that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announced today that Health Canada has approved for use in Canada the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test on the Quidel Triage® MeterPro®, a high-performance, comprehensive testing platform with the smallest footprint analyzer, to aid in the diagnosis of myocardial infarction.

Quidel Corporation today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 variants such as Omicron.

QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced completion of the transaction combining Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company.

Quidel Corporation issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron.

Ortho Clinical Diagnostics Holdings plc announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto.